[Ip-health] Sanofi and DNDi Sign an Innovative Agreement to Generate New Drugs for NTDs

Rachel M. Cohen rachel.cohen72 at gmail.com
Wed Jun 1 10:08:42 PDT 2011

Sanofi and DNDi - Drugs for Neglected Diseases initiative -

Sign an Innovative Agreement to Generate New Drugs

for Neglected Tropical Diseases


Paris, France and Geneva, Switzerland - May 30, 2011 - Sanofi (EURONEXT: SAN

NYSE:SNY) and Drugs for Neglected Diseases initiative (DNDi) announced today
a three-year

research collaboration agreement for the research of new treatments for nine
neglected tropical

diseases (NTDs), listed by the World Health Organization (WHO) for which
new, adapted, and

efficient tools are urgently needed to treat patients in endemic countries.
This agreement is built

upon a history of successful collaboration between Sanofi and DNDi.


In the framework of this agreement, Sanofi will initially bring molecules
from its libraries into the

partnership, while DNDi and Sanofi collaborate in research activities on
innovative molecular

scaffolds. The core of the agreement lies in the innovative management of
intellectual property

generated through the collaboration. The rights to results produced by this
partnership will be coowned

by Sanofi and DNDi. The partners will facilitate publication of the results
to ensure access to

the wider community of researchers focusing on NTDs. The public sector will
benefit from the drugs

developed through this agreement under the best possible conditions to ease
access for patients in

all endemic countries, irrespective of their level of economic development.


“Sanofi is committed to bringing therapeutic solutions to those most
affected and exposed to

neglected tropical diseases (NTDs),” said Dr. Elias Zerhouni, President,
Global Research &

Development, Sanofi. “In this new research collaboration with DNDi, we have
taken a firm step

towards greater flexibility in the sharing of knowledge to produce new


“This agreement is a major milestone in our access to molecules that can
help combat neglected

diseases,” said Dr. Bernard Pécoul, Executive Director of DNDi. “We believe
that this level of

private-sector involvement in open-research collaboration to deliver
appropriate medicines as public

goods is vital to addressing the needs of the most vulnerable populations of
the world. The

agreement allows DNDi to continue making science work more efficiently for
the patients who need

it most. We encourage and commend such engagement.”


Neglected Tropical Diseases covered by the agreement

This agreement covers nine neglected tropical diseases (NTDs): kinetoplastid

(leishmaniases, Chagas disease, and human African trypanosomiasis), helminth

(lymphatic filariasis, onchocerciasis, and soil-transmitted helminthiasis),
and dracunculiasis,

fascioliasis, and schistosomiasis.


Sanofi’s involvement in neglected disease

Sanofi has been involved in the field of NTDs since the 1940s, through
research programmes and

manufacturing of treatments for sleeping sickness and leishmaniasis. In
2001, Sanofi entered into a

partnership agreement with WHO to fight sleeping sickness. In 2006, this
partnership was

expanded to include leishmaniasis, Buruli ulcer, and Chagas disease and
renewed for a further 5

years in 2011. To improve existing drugs and anticipate tomorrow’s
challenges, Sanofi created in

2010, within its Research & Development organization, a Therapeutic
Strategic Unit dedicated to

new anti-infectives. Its scope includes multiresistant bacterial infections
as well as some NTDs.


About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic

solutions focused on patients’ needs. Sanofi has core strengths in the field
of healthcare with seven

growth platforms: diabetes solutions, human vaccines, innovative drugs, rare
diseases, consumer

healthcare, emerging markets and animal health. Sanofi is listed in Paris
(EURONEXT: SAN) and in

New York (NYSE: SNY).


About Drugs for Neglected Diseases initiative (DNDi)

DNDi is a not-for-profit product development partnership working to research
and develop new

treatments for neglected diseases, in particular human African
trypanosomiasis, leishmaniasis,

Chagas disease, malaria, paediatric HIV, and specific helminth-related
infections. DNDi was

established in 2003 by the Oswaldo Cruz Foundation from Brazil, the Indian
Council for Medical

Research, the Kenya Medical Research Institute, the Ministry of Health of
Malaysia, Pasteur

Institute, and Médecins sans Frontières (MSF). WHO/TDR acts as a permanent
observer. Since

2007, DNDi has delivered four products: two fixed-dose anti-malarials (ASAQ
developed with

Sanofi and ASMQ), NECT (nifurtimox-eflornithine combination therapy for
sleeping sickness), and

SSG&PM, a combination therapy to treat visceral leishmaniasis in Africa. For
more information,



Forward Looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform

Act of 1995, as amended. Forward-looking statements are statements that are
not historical facts. These

statements include projections and estimates and their underlying
assumptions, statements regarding plans,

objectives, intentions and expectations with respect to future financial
results, events, operations, services,

product development and potential, and statements regarding future
performance. Forward-looking

statements are generally identified by the words “expects”, “anticipates”,
“believes”, “intends”, “estimates”,

“plans” and similar expressions. Although Sanofi’s management believes that
the expectations reflected in

such forward-looking statements are reasonable, investors are cautioned that
forward-looking information and

statements are subject to various risks and uncertainties, many of which are
difficult to predict and generally

beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those

expressed in, or implied or projected by, the forward-looking information
and statements. These risks and

uncertainties include among other things, the uncertainties inherent in
research and development, future

clinical data and analysis, including post marketing, decisions by
regulatory authorities, such as the FDA or

the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed

for any such product candidates as well as their decisions regarding
labeling and other matters that could

affect the availability or commercial potential of such products candidates,
the absence of guarantee that the

products candidates if approved will be commercially successful, the future
approval and commercial success

of therapeutic alternatives, the Group’s ability to benefit from external
growth opportunities as well as those

discussed or identified in the public filings with the SEC and the AMF made
by Sanofi, including those listed

under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking
Statements” in Sanofi’s annual

report on Form 20-F for the year ended December 31, 2010. Other than as
required by applicable law, Sanofi

does not undertake any obligation to update or revise any forward-looking
information or statements.




Rachel M. Cohen

Regional Executive Director

Drugs for Neglected Diseases initiative (DNDi), North America

40 Wall Street, 24th Floor, New York, NY 10005

Mob: +1.646.824.3064

Office: +1.646.616.8683

Email: rcohen at dndi.org

Web: www.dndi.org <http://www.dndi.org/> 

Best Science for the Most Neglected


More information about the Ip-health mailing list